Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.238 | A prospective, epidemiological, multi-country, cohort study to assess the occurrence of potential bacterial and viral pathogens in stable chronic obstructive pulmonary disease (COPD) and during acute exacerbations of COPD (AECOPD), in moderate to very severe COPD patients, in Asia Pacific. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2014.319 | An observer-blind study to evaluate the safety and immunogenicity of GSK Biologicals’ influenza vaccine(s) GSK3277510A and GSK3277509A administered in adults 18 to 60 years of age. | Prof. HUI David Shu Cheong |
| 2016.096 | A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered intramuscularly on a two-dose schedule to subjects who previously received placebo in ZOSTER-006 and ZOSTER-022 studies. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.122 | Effect of long term Clarithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis in Asian populations | Prof. HUI David Shu Cheong |
| 2019.510 | PREPARE Study: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2018.613 | A randomized, double blind, placebo controlled trial of intravenous N-acetylcysteine and oseltamivir versus intravenous 5% dextrose and oseltamivir alone in adults hospitalized with influenza complicated by lower respiratory tract infection |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.114 | Assessing the risk of exposure and spread of the SARS-CoV-2 virus in the hospital environment |
Dr. HUI David Shu Cheong 許樹昌 |
| 2018.185 | A randomized controlled trial of adjunctive sirolimus and oseltamivir versus oseltamivir alone for treatment of influenza |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.088 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Severe COVID-19 |
Dr. HUI David Shu Cheong 許樹昌 |
| 2020.203 | The safety of high flow nasal cannula and noninvasive ventilation for treatment of patients with COVID-19 complicated by respiratory failure |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2019.451 | A 24-week multi-center, double-blind, placebo controlled dose-range finding study to investigate the efficacy and safety of oral QBW251 in COPD patients on triple inhaled therapy (LABA/LAMA/ICS) |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.220 | Tropism and pathogenesis of SARS-CoV-2 in human macrophages |
Prof. HUI David Shu Cheong 許樹昌 |
| 2019.634 | Screening for lung cancer in subjects with family history of lung cancer. |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2020.508 | Clinical Characteristics of COPD Patients in Hong Kong – An analysis of the Prince of Wales Hospital COPD patients |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2018.250 | Observational study to assess frailty of subjects during ZOSTER-006 and ZOSTER-022 and HZ efficacy, immunogenicity and safety of HZ/su by frailty status. | Prof. HUI David Shu Cheong |
| 2020.229 | Long-term longitudinal comparisons of health and immunity status in convalescent COVID-19 and vaccinated cohorts in Hong Kong |
Prof. HUI David Shu Cheong 許樹昌 |
| 2020.089 | A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment |
Dr. HUI David Shu Cheong 許樹昌 |
| 2018.433 | A PHASE III, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BALOXAVIR MARBOXIL IN COMBINATION WITH STANDARD-OF-CARE NEURAMINIDASE INHIBITOR IN HOSPITALIZED PATIENTS WITH SEVERE INFLUENZA |
Prof. HUI David Shu Cheong 許樹昌 |
| 2019.392 | A phase III, randomized, observer-blind, placebo controlled, multicenter clinical trial to assess Herpes Zoster recurrence and the reactogenicity, safety and immunogenicity of GSK Biologicals’ Herpes Zoster vaccine (HZ/su) when administered intramuscularly on a 0 and 2 month schedule to adults ≥ 50 years of age with a prior episode of Herpes Zoster. |
Prof. HUI David Shu Cheong 許樹昌 |
| 2024.481 | SA-BioPercept study: A survey study on biologics initiation from the perspective of moderate-tosevere asthma patients | Prof. HUI David Shu Cheong |
| 2024.207 | A study to evaluate the consistency of oscillometry and spirometry test results in patients with confirmed or suspected asthma or COPD |
Prof. Hui David Shu Cheong 許樹昌 |
| 2024.628 | A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Dose Range-Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 Given Once Daily for 12 Weeks in Adults with Uncontrolled Asthma at Risk of Exacerbations (LEVANTE) | Prof. HUI David Shu Cheong |
| 2025.022 | BRISOTE: A Multicentre, Randomised, Double-Blind, Parallel Group, Active-Controlled, Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium-Dose Inhaled Corticosteroid Plus Long-acting β2-Agonist | Prof. HUI David Shu Cheong |
| 2024.240 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma | Prof. HUI David Shu Cheong |
| 2024.428 | The disease burden of RSV infection in Hong Kong | Prof. HUI David Shu Cheong |
| 2022.412 | Study on Clinical Use of EVUSHELD (AZD7442) in the Real-world Setting – A Multicentre, Single-arm, Observational Study to Determine the Utilisation and Clinical Outcomes of EVUSHELD in China |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2021.298 | Prevalence of non-alcoholic fatty liver disease among non-obese obstructive sleep apnea by using transient elastography | Prof. HUI David Shu Cheong |
| 2023.628 | Long-term longitudinal comparisons of health status and immune responses in elderly cohorts with seasonal influenza vaccine in Hong Kong | Prof. HUI David Shu Cheong |
| 2021.032 | A PHASE III OPEN LABEL EXTENSION STUDY TO EVALUATE LONG TERM SAFETY AND EFFICACY OF PRM 151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) |
Prof. HUI David Shu Cheong 許樹昌教授 |
| 2022.407 | A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow- up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of immune response of a Herpes Zoster subunit vaccine and assessment of persistence of immune response and safety of 1 or 2 additional doses administered in ZOSTER-049 in 2 subgroups of older adults. | Prof. HUI David Shu Cheong |
| 2022.646 | Early Prednisolone for Suspected Community-acquired Acute Respiratory Tract Infection (PREDICATE): A Double-blind, Randomised, Multi-centre, Adaptive Platform, Controlled Trial | Prof. HUI David Shu Cheong |
| 2011.312 | Ethnic and Gender Comparison of Craniofacial Phenotypes in Obstructive Sleep Apnoea | Prof Hui David SC Hui |
| 2011.005 | Validation of the new COPD Assessment Test (CAT) translated into Chinese in patients with Chronic Obstructuve Pulmonary Disease (COPD) | Prof Hui David SC Hui |
| 2014.345 | Obstructive sleep apnoea and CPAP treatment response in patients with non-alcoholic fatty liver disease | Prof. HUI David S.C. |
| 2009.451 | A Pilot Phase 2, Open-Label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult Hospitalized Subjects with Confirmed Pandemic H1N1 Influenza Infection | Prof Hui David |
| 2020.012 | Spousal coordination across transition to parenthood: Its associations with physical and psychological well-being |
Dr. HUI Chin Ming 許展明 |
| 2019.067 | The influence of emotion regulation on physiological changes in couple conflict discussion |
Dr. HUI Chin Ming 許展明 |
| 2019.066 | Spousal coordination across transition to parenthood: Its prenatal antecedents and links with health and relationship well-being |
Dr. HUI Chin Ming 許展明 |
| 2020.340 | Response after End of Treatment with Antivirals in Chronic Hepatitis B |
Dr. HUI Aric Josun 許祖紳 |
| 2019.550 | CATALYST 207: A PHASE 2, PILOT, EXPLORATORY STUDY EVALUATING THE SAFETY AND ANTIVIRAL EFFICACY OF INARIGIVIR SOPROXIL IN NON-CIRRHOTIC TREATMENT-NAÏVE SUBJECTS INFECTED WITH CHRONIC HEPATITIS B VIRUS |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2015.585 | The Hong Kong HCV Registry |
Dr. HUI Aric Josun 許祖紳 |
| 2017.531 | A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment |
Dr. HUI Aric Josun 許祖紳醫生 |
| 2017.164 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis |
Dr. HUI Aric Josun 許祖紳 |
| 2015.290 | Direct Discharge of Patients with Upper gastrointestinal bleeding from the Emergency Department after Endoscopy: A Feasibility Study |
Dr. HUI Aric Josun 許祖紳 |
| 2014.590 | CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects with Liver Fibrosis | Dr. HUI Aric Josun |
| 2014.591 | A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region | Dr. HUI Aric Josun |
| 2017.165 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH) |
Dr. HUI Aric Josun 許祖紳 |
| 2014.610 | A Risk Score derived from a large Gastrointestinal Bleeding Registry with Retrospective Validation | Dr. HUI Aric Josun |
| 2012.421 | Double Balloon Enteroscopy in Hong Kong: Six years experience at a Single Center | DR HUI ARIC JOSUN |
| 2011.591 | Serum hepatitis B surface antigen levels to guide the stopping of entecavir in HbeAg-negative chronic hepatitis B | Dr Hui Aric Josun |
Page 159 of 262.